The "Mummy of Erba": A study proposal for the analysis of a mummified Egyptian specimen

The so-called "Mummy of Erba" is an Egyptian specimen housed in the Civic Museum of Erba, consisting of three embalmed parts, a head, a left hand and a foot. As intact contexts, mummies allow to conduct comprehensive studies on all the preserved tissues, offering the possibility to analyze them through the non-invasive Radiodiagnostic methods, without proceeding to the unwrapping. The study we present is a proposal to analyze the mummy with a multidisciplinary approach, in order to acquire anthropological, paleopathological, archaeometric and archaeological data on this preserved specimen. Finally, this contribution is aimed at exposing all the provided methodologies with a view to conducting a complete analysis of the sample

\u201cMummies outside their closets\u201d. Paleoradiological investigation of Egyptian mummified remains

Paleoradiological investigations of three mummified remains housed in the archaeological museum of Erba allowed us to investigate the origin, biological profile, embalming techniques and pathological conditions of finds unknown until now. These mummified remains, belonging to the private collection of the Majnoni family, were donated to the museum without any information about their origin. We are well aware of the past issue on the commercialization of mummified remains and of the low possibility for anthropologists to have access to ancient mummies. For this reason our intent is to stimulate curators of small collections to contact team of anthropologists, radiologists and paleopathologists to grant the study of finds housed in museums with the aim of obtaining more information about the anthropological cultural heritage

A radiation hard bipolar monolithic front-end readout

A fast bipolar monolithic charge sensitive preamplifier (CSP), implemented in the monolithic 2m BiCMOS technology (called HF2CMOS) was designed and built in a quad monolitic chip. Studies of radiation effects in the CSP performance, from non-irradiated and up to neutron irradiation of 5.3x1014n/cm2, have confirmed that the use of bipolar npn transistors is suitable for the radiation level of the future LHC collider environment. The CSP presents a new circuit solution for obtaining adequate slew rate performances which results in an integral linearity better than 0.8% on 5 V at 20 ns of shaping time, regardless of the bias current selected for the CSP. This way the bias current of the CSP can be set for optimizing the power dissipation with respect to series and parallel noise, especially useful when the CSP is put in a radiation environment. A prototype test with a novel monolithic 20 ns time constant RC-CR shaper, capable to sum up four inputs has been also realized, featuring good integral linearity

Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction

Aims to compare the efficacy and safety of lanoteplase, a single-bolus thrombolytic drug derived from alteplase tissue plasminogen activator, with the established accelerated alteplase regimen in patients presenting within 6 h of onset of ST elevation acute myocardial infarction. Methods and Results 15 078 patients were recruited from 855 hospitals worldwide and randomized in a 2:1 ratio to receive either lanoteplase 120 KU. kg-1 as a single intravenous bolus, or up to 100 mg accelerated alteplase given over 90 min. The primary end-point was all-cause mortality at 30 days and the hypothesis was that the two treatments would be equivalent. By 30 days, 6.61% of alteplase-treated patients and 6.75% lanoteplase-treated patients had died (relative risk 1.02). Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). The net clinical deficit of 30-day death or non-fatal disabling stroke was 7.0% and 7.2%, respectively. By 6 months, 8.8% of alteplase-treated patients and 8.7% of lanoteplase-treated patients had died. Conclusion Single-bolus weight-adjusted lanoteplase is an effective thrombolytic agent, equivalent to alteplase in terms of its impact on survival and with a comparable risk-benefit profile. The single-bolus regimen should shorten symptoms to treatment times and be especially convenient for emergency department or out-of-hospital administration. (C) 2000 The European Society of Cardiology